| 22.07 0.17 (0.78%) | 10-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 29.19 | 1-year : | 34.1 |
| Resists | First : | 25 | Second : | 29.19 |
| Pivot price | 22.09  |
|||
| Supports | First : | 21.2 |
Second : | 18.86 |
| MAs | MA(5) : | 23.25 |
MA(20) : | 21.86 |
| MA(100) : | 18.11 |
MA(250) : | 17.51 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 45.7 |
D(3) : | 63 |
| RSI | RSI(14): 54 |
|||
| 52-week | High : | 27.2 | Low : | 9.89 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ VRDN ] has closed above bottom band by 49.6%. Bollinger Bands are 64.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 22.27 - 22.4 | 22.4 - 22.53 |
| Low: | 21.34 - 21.5 | 21.5 - 21.65 |
| Close: | 21.83 - 22.06 | 22.06 - 22.28 |
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Thu, 23 Oct 2025
Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Viridian Therapeutics (VRDN) - The Globe and Mail
Wed, 22 Oct 2025
Viridian Therapeutics (VRDN): What Recent Volatility Means for Shareholders and Valuation - simplywall.st
Wed, 22 Oct 2025
Viridian Therapeutics (VRDN) Launches $251.35M Share Offering - GuruFocus
Tue, 21 Oct 2025
Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock - Business Wire
Tue, 21 Oct 2025
Viridian Therapeutics launches public offering of common stock - Investing.com
Tue, 21 Oct 2025
Viridian Therapeutics (VRDN) Is Up 15.9% After $300 Million Royalty Deal to Fund Thyroid Eye Drug – Has The Bull Case Changed? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 82 (M) |
| Held by Insiders | 6.694e+007 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 11,570 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.711e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -142 % |
| Return on Assets (ttm) | 356 % |
| Return on Equity (ttm) | -39.8 % |
| Qtrly Rev. Growth | 305000 % |
| Gross Profit (p.s.) | 7.77 |
| Sales Per Share | -122 |
| EBITDA (p.s.) | -5.63463e+008 |
| Qtrly Earnings Growth | -3.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -309 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.19 |
| Price to Cash Flow | 2.97 |
| Dividend | 0 |
| Forward Dividend | 1.024e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|